Sharp Clinical Services   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Conshohocken PA United States (1952)
Status: No NME R&D (1952)

Organization Overview

First Clinical Trial
2015
NCT02279524
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Sharp Clinical Services | Sharp Clinical Services, Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

aramchol (1 trial)

Drugs in Phase 2 Trials (1)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (1)

acetylsalicylic acid (aspirin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3